# A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

> **NCT06844474** · PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** SHR-1826；Adebrelimab；SHR-8068；Bevacizumab

## Key facts

- **NCT ID:** NCT06844474
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-07
- **Primary completion:** 2026-08-31
- **Final completion:** 2028-02-29
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844474, "A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06844474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*